Russian cancer research team gains international funding

The international research project ‘The Definition of new types of tumours containing potential mutations sensitivity to drugs’ has begun in Petrov Research Institute of Oncology in St Petersburg, the oldest Russian oncology institute.

Evgeny N Imyanitov
Evgeny N Imyanitov

The project, funded by the international biopharmaceutical company AstraZeneca Pharmaceuticals, is Russia’s first experience of this kind of cooperation in fundamental science between a pharmaceutical company and a scientific research institute.

The main aim of the project is to search for new ‘targets’ for effective chemotherapy, under lead researcher Professor Evgenij Imjanitov, Head of the institute’s Tumour Growth Biology Department. The biopharmaceutical company has allocated about $500,000 and the Research Institute of Oncology has donated Europe’s largest collection of tumours (about 1million samples). Researchers have to choose the most common types of malignant formations (about 28 tumours) and examine them for the presence of gene mutation targets. The diagnostic value of genetic damage in tumours has become obvious to scientists only in this century. The most striking example is the detection of mutations in the epidermal growth factor receptor: tumour cells, which have the mutation, have a unique sensitivity to target drugs.

‘Unfortunately,’ the professor observes, ‘mutations of the gene of epidermal growth factor receptor were so far found only in lung cancer, and systematic studies of other tumours have not been carried out yet. Besides, there are about 60 genes similar in its structure in the group, and they may also get mutations, which are the potential targets for therapy. Finally, researchers should remember that the spectrum of mutations in different countries has regional characteristics: patients are unlike the gene pool, and therefore the search for targets is relevant to each individual country.
 

PROFILE

Evgeny N Imyanitov heads the Tumour Growth Biology Department at N.N. Petrov Institute of Oncology; the Medical Genetics Department at St Petersburg Paediatric Medical Academy, and Professor at the Oncology Department, Medical Academy for Postgraduate Studies. He graduated from I.P. Pavlov Medical School in 1989, gained his PhD from N.N. Petrov Institute of Oncology in 1992, and the IARC Fellowship for post-doctoral training in the Max Planck Institute of Biochemistry in Munich. In 1996 he established his research group at the St Petersburg institute to focus on translational aspects of cancer science – making a substantial contribution in hereditary cancer syndromes. His team also studies basic aspects of cancer pathogenesis (investigations of molecular features of bilateral breast cancer).
 

21.03.2013

Read all latest stories

Related articles

Photo

News • BRCA and prostate, pancreatic cancers

Faulty 'breast cancer gene' BRCA also dangerous for men

Faulty versions of the BRCA1 and BRCA2 genes are well known to increase the risk of breast and ovarian cancer. Now, they have been linked to several other cancers, including those that affect men.

Photo

Interview • International research collaboration

The Pan-Cancer project: Cancer development begins within the genes

Launched in 2011, the Pan-Cancer Project, involved more than 1,300 scientists and clinicians in 37 countries, and analysed more than 2,600 genomes of 38 tumour types. Discovery: The first indications…

Photo

News • Regenerative medicine

Blood cells can be directly reprogrammed into neural stem cells

Scientists from the German Cancer Research Center (DKFZ) and the stem cell institute HI-STEM* have succeeded for the first time in directly reprogramming human blood cells into a previously unknown…

Related products

Canon – Alphenix 4D CT

Multi-Modality Suites

Canon – Alphenix 4D CT

Canon Medical Systems Europe B.V.
Canon - Aquilion Exceed LB

Oncology CT

Canon - Aquilion Exceed LB

Canon Medical Systems Europe B.V.
Canon – Aquilion LB

Oncology CT

Canon – Aquilion LB

Canon Medical Systems Europe B.V.
Canon – Vitrea Advanced Visualization

Reading

Canon – Vitrea Advanced Visualization

Canon Medical Systems Europe B.V.
CliniSys | MIPS – MIPS GLIMS genetics

LIS, Middleware, POCT

CliniSys | MIPS – MIPS GLIMS genetics

CliniSys | MIPS Deutschland GmbH
Subscribe to Newsletter